August 18, 2026 02:34 PM GMT CSL Ltd | Asia Pacific M Idea Back on track What's Changed CSL Ltd (CSL.AX) From To Price Target A$163.00 A$172.00 CSL's FY26 result and FY27 guidance highlight an improved growth profile for CSL Behring. Remain OW. Key Takeaways What was interesting: (1) Ig revenue rose 7% YoY (constant currency/CC) in 2H26, with positive HoH trends (+4% vs. 1H26). For FY27, CSL expects Ig revenue to grow in line with the market (mid- to high single digits; we expect +7% in FY27E). (2) Albumin ...

18 Aug 2026 08:53:27 ET │ 14 pages CSL Ltd (CSL.AX) The worst seems past, base case mid single-digit mid-term NPAT growth CITI'S TAKE CSL's FY27 NPAT guide was ahead of VA consensus (5% growth vs 1-2% growth CC) but generated a strong stock price reaction (+17%). Our new PT is AUD160 (from AUD110) which is mainly a product of rolling our DCF valuation and adjusting the peer PE multiple we apply from 9x to 14x for our blended valuation method, as global therapeutics names have seen more of a bid recently. He ...